<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We describe a patient with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> with <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>-related changes (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-MRC) that clinically resembled <z:hpo ids='HP_0004836'>acute promyelocytic leukemia</z:hpo> (APL) </plain></SENT>
<SENT sid="1" pm="."><plain>The karyotype of his leukemic cells was 46, XY, del (3) (q?) and did not include a chromosomal translocation involving the <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> receptor-Î± gene </plain></SENT>
<SENT sid="2" pm="."><plain>However, <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> syndrome developed, and partial remission was achieved after treatment with <z:hpo ids='HP_0000001'>all</z:hpo>-trans <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> (ATRA) followed by chemotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>Our case might provide new insights into the mechanism of the growth inhibitory effect of ATRA on APL-like cells </plain></SENT>
</text></document>